Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 33INDUSTRY 26UNKNOWN 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

apatinib 3Drug Therapy 3icotinib 2camrelizumab 2Radiotherapy 2Etoposide 2Erlotinib Hydrochloride 2Cisplatin 2tislelizumab 1pembrolizumab 1aumolertinib 1anlotinib 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Povidone-Iodine 1Pleurodesis 1Pemetrexed 1Nutrition Assessment 1Methylene Blue 1Lidocaine 1Irinotecan 1Indocyanine Green 1Immunotherapy 1Gemcitabine 1Gefitinib 1Chemoradiotherapy 1Celecoxib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × icotinib × Thoracic × Clear all
NCT02960607 2016-11-18

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

ChineseAMS

Phase 2 Unknown
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02961270 2016-11-11

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

ChineseAMS

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡